Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Broto

Showing results (461-470 of 555) with videos related to

Pageof 56
Sort By:
The Oncologist|July 30, 2017
Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part SarcomaSilvia Stacchiotti, Olivier Mir, Axel Le Cesne, et al.
European Journal of Cancer (Oxford, England : 1990)|February 24, 2018
High-risk soft tissue sarcomas treated with perioperative chemotherapy: Improving prognostic classification in a randomised clinical trialSandro Pasquali, Chiara Colombo, Sara Pizzamiglio, et al.
Journal for Immunotherapy of Cancer|November 18, 2020
Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trialJavier Martin-Broto, Nadia Hindi, Giovanni Grignani, et al.
Lancet (London, England)|March 9, 2026
Pimicotinib versus placebo for tenosynovial giant cell tumour (MANEUVER): an international, randomised, placebo-controlled, phase 3 trialHairong Xu, Xiaohui Niu, Vinod Ravi, et al.
Molecular Cancer Therapeutics|October 23, 2013
MRP1 overexpression determines poor prognosis in prospectively treated patients with localized high-risk soft tissue sarcoma of limbs and trunk wall: an ISG/GEIS studyJavier Martin-Broto, Antonio M Gutierrez, Rafael F Ramos, et al.
Cancers|August 10, 2024
Ibero-American Consensus for the Management of Peritoneal Sarcomatosis: Updated Review and Clinical RecommendationsFrancisco Cristóbal Muñoz-Casares, Javier Martín-Broto, Pedro Cascales-Campos, et al.
JAMA|April 8, 2020
Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical TrialWilliam D Tap, Andrew J Wagner, Patrick Schöffski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2026
Safety and Efficacy of Epirubicin, Ifosfamide, and Nivolumab as First-line treatment for patients with Undifferentiated Pleomorphic SarcomaJavier Martin-Broto, Javier Martinez-Trufero, Roberto Diaz-Beveridge, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 17, 2010
Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: a Spanish Group for Sarcoma Research (GEIS) StudyJ Martin-Broto, A Gutierrez, X Garcia-Del-Muro, et al.
JAMA Oncology|March 30, 2023
Effectiveness and Safety of Trabectedin and Radiotherapy for Patients With Myxoid Liposarcoma: A Nonrandomized Clinical TrialRoberta Sanfilippo, Nadia Hindi, Josefina Cruz Jurado, et al.
Pageof 56

Showing results (461-470 of 555) with videos related to

Sort By:
Pageof 56
The Oncologist|July 30, 2017
Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part SarcomaSilvia Stacchiotti, Olivier Mir, Axel Le Cesne, et al.
European Journal of Cancer (Oxford, England : 1990)|February 24, 2018
High-risk soft tissue sarcomas treated with perioperative chemotherapy: Improving prognostic classification in a randomised clinical trialSandro Pasquali, Chiara Colombo, Sara Pizzamiglio, et al.
Journal for Immunotherapy of Cancer|November 18, 2020
Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trialJavier Martin-Broto, Nadia Hindi, Giovanni Grignani, et al.
Lancet (London, England)|March 9, 2026
Pimicotinib versus placebo for tenosynovial giant cell tumour (MANEUVER): an international, randomised, placebo-controlled, phase 3 trialHairong Xu, Xiaohui Niu, Vinod Ravi, et al.
Molecular Cancer Therapeutics|October 23, 2013
MRP1 overexpression determines poor prognosis in prospectively treated patients with localized high-risk soft tissue sarcoma of limbs and trunk wall: an ISG/GEIS studyJavier Martin-Broto, Antonio M Gutierrez, Rafael F Ramos, et al.
Cancers|August 10, 2024
Ibero-American Consensus for the Management of Peritoneal Sarcomatosis: Updated Review and Clinical RecommendationsFrancisco Cristóbal Muñoz-Casares, Javier Martín-Broto, Pedro Cascales-Campos, et al.
JAMA|April 8, 2020
Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical TrialWilliam D Tap, Andrew J Wagner, Patrick Schöffski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2026
Safety and Efficacy of Epirubicin, Ifosfamide, and Nivolumab as First-line treatment for patients with Undifferentiated Pleomorphic SarcomaJavier Martin-Broto, Javier Martinez-Trufero, Roberto Diaz-Beveridge, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 17, 2010
Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: a Spanish Group for Sarcoma Research (GEIS) StudyJ Martin-Broto, A Gutierrez, X Garcia-Del-Muro, et al.
JAMA Oncology|March 30, 2023
Effectiveness and Safety of Trabectedin and Radiotherapy for Patients With Myxoid Liposarcoma: A Nonrandomized Clinical TrialRoberta Sanfilippo, Nadia Hindi, Josefina Cruz Jurado, et al.
Pageof 56